Who We Are
What We Do
For Patients
Resources
What's New
Locations
Select
Overview
Evaluation and Diagnosis
• In-Office Ultrasound
• Mammography
• PET/CT Scan
• MRI
Breast Biopsy
Benign Conditions of the Breast
• Cryoablation of
   Fibroadenomas
• Breast Pain
• Cyst Aspiration
High Risk Evaluation
• Risk Factors for
   Breast Cancer

• Ductal Evaluation
• Genetic Testing
• Lobular Carcinoma
   In Situ
Care of the Breast Cancer Patient

• After Surgical Treatment
  of Breast Cancer
• Lumpectomy
• Mastectomy
• Sentinel Node Biopsy
• Axillary Lymph Node
   Dissection
• Lymphedema
• Breast Reconstruction
• Radiation Therapy

Research
 
Print this information
High Risk Evaluation

Lobular Carcinoma In Situ

What is Lobular Carcinoma In Situ?
Lobular Carcinoma in situ (LCIS) is not a breast cancer, but rather a high risk marker for
potential development of breast cancer in either breast in the future. Most lobular carcinoma in situ is diagnosed by a woman having a breast biopsy and is found at that time. Most women diagnosed with LCIS can be managed by close observation. However, the Breast Cancer Prevention Trial demonstrated that in a subgroup of women being followed with LCIS (826) risk was reduced by 56% by taking Tamoxifen.
In our practice, we follow women with Lobular Carcinoma In Situ closely at 6 month interval visits. We discuss options for chemoprevention or treatment with Tamoxifen, MRI, and lifestyle modification.

 

 

 

 

 

 

 

 
 
Print this information
 
© 2005 The Center for Advanced Breast Care info@AdvancedBreastCare.net Disclaimer